AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site
YOKOHAMA, Japan, Nov 17 (Bernama) -- While there is growing interest and momentum for cell and gene therapy development in Japan, there are a limited number of CDMOs with the institutional knowledge, manufacturing prowess, talent development, and international network. To advance their projects in a fast-paced, resource-constrained environment, three biopharma developers including the Institute of Science Tokyo have selected AGC Biologics to provide cell therapy services from its new Yokohama location.
AGC established its cell therapy services in Yokohama in July 2025, bringing together two strong legacies: thirty years of expertise and the track record of the AGC Biologics Milan site, and AGC Group’s century-plus manufacturing excellence in Japan. Combined, those legacies position AGC to meet the burgeoning needs of the cell and gene therapy industry.